Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. Conclusion: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Indirect evidence to demonstrate that slow pot-prandial gastric emptying should not result in substantial gastric retention 12 hours after the last meal. (A) Six-hour gastric emptying tests (13C- octanoate breath for labeling solid meal components) analyzed using Wagner-Nelson equations were performed in 47 T2D subjects at baseline (black curves, with dotted lines indicating ± 95% confidence intervals). Results from subjects with substantially decelerated gastric emptying (at baseline or 10 weeks after initiating treatment with lixisenatide [20 µg/d] or liraglutide [1.8 mg/d]) are also shown. Gastric emptying curves between 6.5 and 12 hours after meal intake were interpolated assuming an exponential decay (from an initial plateau of 100%) based on the measurements during the initial 6 hours. Even those with slow gastric emptying achieved a gastric content near 0% by 12 hours, which would be a typical interval between a last meal (eg, dinner at 7 Pm) and an early procedure (endoscopy or general anesthesia) in the morning of the following day. Data used for display and modeling are from Quast et al (40). (B) Residual gastric content from food ingested on the previous day (or earlier) as visualized in the gastric antrum by upper gastrointestinal tract endoscopy (courtesy Diabetes Center Bad Lauterberg). Abbreviations: T2D, type 2 diabetes.](https://figures.cochat.ai/paper-figures/7d35bedb7ee940febd956b76a9173f53/clinical-consequences-of-delayed-gastric-emptying-with-glp-1-receptor-agonists-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of its GLP-1 component also delays gastric emptying, blunting postprandial glucose excursions and contributing to steadier overall glucose profiles [69].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second is pharmacokinetic: GLP-1 agonists slow gastric emptying and so alter the absorption rate of oral drugs [47,120], while berberine inhibits enzymes and transporters at the same intestinal interface, so the two perturb one process from different directions [46,47].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [120]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This difference is believed to result from tachyphylaxis associated with prolonged GLP-1 RA use, leading to attenuation of the gastric emptying–delaying effect, which becomes more evident with long-acting formulations [32,33].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Based on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and…”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“Monnier at al reported that PPG is a dominant contributor to overall glycemia in T2D (as assessed by measurement of hemoglobin A 1c ), especially in well-controlled diabetes [calculated to contribute approximately 70% when hemoglobin A 1c is ≤ 7.3% (3)].”
InfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“…on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and obesity.”
Identifying and Avoiding Bias in Research
Pannucci, C. J., & Wilkins, E. G. (2010) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e3181de24bc · Cited by 1,079 · cited 1×
“…to see what one expects to see (eg, in studies where the examiner was not blinded to the patients ’ health status or treatment); publication bias describes the fact that results not compatible with the original hypothesis have a lesser chance to be submitted or accepted for publication (116).”
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“…refer to Supplementary Table S1 for more data on the effect of GLP-1 receptor agonists on gastric emptying in subjects with type 2 diabetes and obesity. imprecise measurement techniques (31) like the paracetamol (acetaminophen) absorption technique, which continues to be used extensively (32-34).”
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 1×
“While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through both parasympathetic (vagal) afferents and direct central nervous stimulation (85-87).”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“Accordingly, a possible mechanism of action of GLP-1 RAs to reduce appetite and energy intake may involve interaction with neurons in the hypothalamus either directly (66, 67) or via the nodose ganglion (68), rather than a secondary consequence of slowing gastric emptying.”
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 1×
“This dose-dependent slowing of gastric emptying represents a major mechanism contributing to PPG lowering by exogenous GLP-1 and, in healthy humans, “ outweighs ” its insulinotropic effects such that postprandial insulin secretory responses are suppressed rather than stimulated (15, 16).”
Self-citationVantrappen, G., Janssens, J., Hellemans, J., & Ghoos, Y. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108740 · Cited by 815 · cited 1×
“…phase 3 of this complex, which is composed of pressure waves often originating in the stomach and propagated segment by segment toward the duodenum and jejunum (108), which is thought to clear the remnants of the preceding meal including indigestible gastric content from the stomach (108, 109).”
Clinical Significance of Pulmonary Aspiration during the Perioperative Period
Warner, M. A., Warner, M. E., & Weber, J. G. (1993) · Anesthesiology · doi:10.1097/00000542-199301000-00010 · Cited by 808 · cited 1×
“This is a rare complication of general anesthesia, with an incidence of approximately 1 per 3000 elective surgery cases, resulting in death in approximately 1 per 70 000 cases (106).”
Research works printed but not linked: 3
- Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V, Classen M. Glucagon-like peptide (GLP)-1(7-36)-amide: a central suppressor of food intake in rats (abstract). Gastroenterol. 1992; 102: A756.
- Code CF, Schlegel JF. The gastrointestinal interdigestive housekeeper: motor correlates of the interdigestive myoelectric complex of the dog. In: Daniel EE, Gilbert JAL, Schofield B, Schnitka TK, Scott G, eds. Proceedings of the Fourth International Symposium on Gastrointestinal Motility. Vancouver Mitchell Press Ltd.; 1974: 631‐ 634.
- American Gastroenterological Association. AGA does not endorse all patients stopping popular diabetes and weight loss drugs prior to endoscopy. 2023. Accessed May 28, 2024. https://gastro.org/press-releases/continue-glp1-drugs-before-endoscopy/
Cited by
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Self-citationUllah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“The maximum duration of any of the few studies in which a good technique has been used to quantify emptying (usually scintigraphy) is 16 weeks, and while the magnitude of the delay in emptying at that time point was not as marked as at 5 weeks, it was substantial in some cases (47).”
Self-citationCedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 28
Vlaeminck, N., de Putte, P. B. C. V., Dekeyser, M., Baert, N., Wallyn, A., Vernieuwe, L., Smitz, C. J., Wouters, K., Cauwenberghe, J. V., & Saldien, V. (2026) · Anaesthesia · doi:10.1111/anae.70129 · Cited by 23
“One hypothetical mechanism is that GLP-1 RAs interfere with the interdigestive migrating motor complex, which clears the indigestible remnants of the preceding meal from the stomach [21].”
Goldenberg, R., Gilbert, J. D., Houlden, R. L., Khan, T., Makhija, S., Mazer, C. D., Trinacty, J., & Verma, S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2458538 · Cited by 23
“The same authors also proposed that weekly GLP-1RAs can be continued but that short-acting GLP-1RAs should be withheld for 48 h and liraglutide for > 5 days before a procedure ─ this hold is notably longer than that endorsed by others 77 .”
InfluentialLlach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 20
“GLP-1RAs are known to delay gastric emptying [247], which could theoretically affect the absorption of co-administered medications.”
Ariaee, A., Noueihad, K., Hunter, A., Wignall, A. D., Wardill, H. R., Davies, M. R., Prestidge, C. A., & Joyce, P. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114711 · Cited by 14
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
“While a direct role for GLP-1RA-mediated slowing of gastric emptying in these events has not been well studied, various clinical recommendations have been proposed to limit patient risk [16].”
InfluentialGLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“Retained gastric contents during upper gastrointestinal endoscopy are more frequently observed in patients on GLP-1 receptor agonists [118].”
Niu, C., Sun, K., Zhang, J., Elkhapery, A. M. R., Zhu, K., Malik, S., Xue, C., & Okolo, P. I., III (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003760 · Cited by 18
Lim, E. C. N., & Lim, C. E. D. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02079-9 · Cited by 17
“GLP-1 receptor agonists exert their gastric effects through complex neurally-mediated mechanisms rather than direct gastric smooth muscle actions [13].”
Vetrugno, L., Deana, C., Porto, A. D., Boero, E., Bellini, V., Biasucci, D. G., & Bignami, E. G. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00237-y · Cited by 14
“On the other hand, much evidence from large retrospective cohorts with endoscopic evaluation of gastric content has proven the association between incretin-based therapy exposure and increased retained gastric content [21].”
Mustafa, Y. F. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100620 · Cited by 11
Food regulation of incretin axis: Molecular mechanisms and clinical outlook in diabetes
Huang, Q., Deng, H., Sun, M.-C., & Zhao, C. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105326 · Cited by 9
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“63,67 However, interpretation of these findings requires caution, as diagnostic confirmation of gastroparesis is challenging, and gastric emptying scintigraphy— the diagnostic gold standard—is not consistently performed in routine clinical practice.”
Clinical roles of point-of-care ultrasonography in airway management
Seo, H., Oh, C.-S., Choi, G. J., & Park, J. (2025) · Anesthesia and Pain Medicine · doi:10.17085/apm.25346 · Cited by 8
“This effect may persist for several days after the last dose, potentially exceeding standard pre-operative fasting intervals [39].”
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
Crespo, J., Rodríguez-Duque, J. C., Iruzubieta, P., Cerda, E. C. M., & Velasco, J. A. V.-R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155597 · Cited by 9
“Gastric adaptation after 12–16 weeks reduces, but does not normalize, RGC rates [6].”
InfluentialJogani, V. G., Elfadil, O. M., Varayil, J. E., & Mundi, M. S. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001294 · Cited by 10
Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Witaszek, T., Biesiada, A. M., Iskra-Trifunović, J., Babicki, M., Mastalerz–Migas, A., & Kłoda, K. (2025) · Biomedicines · doi:10.3390/biomedicines13102362 · Cited by 8
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Self-citationZambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
“One of the primary mechanisms contributing to both weight loss and GI adverse events is delayed gastric emptying [40].”
InfluentialCano, R., Rodríguez, D. L., Durán, P., Cano, C., Rojas-Gómez, D. M., Rivera-Porras, D., Barboza-González, P., Fuentes-Barría, H., Angarita, L., Boscan, A., et al. (2025) · Nutrients · doi:10.3390/nu17193123 · Cited by 10
“And then through antroduodenal coordination, it is directed toward the pyloric canal and proximal duodenum [40–42].”
Umapathysivam, M. M., Araldi, E., Hastoy, B., Dawed, A. Y., Vatandaslar, H., Mayrhofer, J. E., Lindquist, P., Silva, P. N., Goga, A., Trüllinger, G. O., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01630-0 · Cited by 15
Self-citationWeight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Obesity management before and after pancreas transplantation
Abbasi, A. B., Posselt, A. M., Orandi, B. J., Odorico, J. S., & Stock, P. G. (2025) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001226 · Cited by 6
Aspiration Risk During Endoscopic Procedures While on GLP-1 Agonist Therapy
Stryelkina, M., Molina, R., Janice, T., Ancha, A., Bejcek, J., Ian, F., Mullarkey, M., & Johnson, C. T. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09307-1 · Cited by 4
Lorenz, N., Stauffer, J. R., Abouafech, A., Mourad, A., & Bray, K. (2025) · Cureus · doi:10.7759/cureus.90657 · Cited by 4
“As a motilin receptor agonist, erythromycin exerts prokinetic effects on the upper GI tract, and emerging studies suggest it may reverse GLP-1-related delays in gastric emptying [13,14].”
The ‘Obesity First’ approach: Redefining the future of healthcare
Mulder, C. J. J., Bayoumy, A. B., & Ansari, A. R. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01882-5 · Cited by 7
“In cases of constipation, early intervention with macrogol and adequate fluid intake should be advised [30].”
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
PBPK Modeling Addresses Oral Absorption-Mediated Drug Interactions
Zhang, X., Fraczkiewicz, G., & Lukáčová, V. (2026) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2026.101523 · Cited by 3
Glucagon-like peptide-1 receptor agonists: a review of the literature from a dental perspective
O'Driscoll, J. A., & McIntyre, G. T. (2026) · BDJ · doi:10.1038/s41415-025-9345-4 · Cited by 3
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“These agents exert powerful central and gastrointestinal effects that suppress appetite, slow gastric emptying, and reduce overall energy intake [13 – 15].”
InfluentialRutigliani, G., & Mattes, R. D. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115486 · Cited by 4
Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide
Iskander, M., Wadhwa, M., Kim, Y. J., Singh, N. C., & Pathak, P. (2025) · Cureus · doi:10.7759/cureus.78090 · Cited by 4
“Several studies have demonstrated a higher risk of retained gastric contents with the use of GLP-1 RAs [8].”
SAFE anaesthesia for patients at risk of pulmonary aspiration: A nationwide survey
Baettig, S. J., Filipovic, M. G., Giroud, M., Bomberg, H., Hofer, C. K., Eichenberger, U., & Ganter, M. T. (2025) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000070 · Cited by 4
Bortolotti, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i23.104932 · Cited by 2
“However, in patients with DG, to minimize the risk of regurgitation events and pulmonary aspiration many major societal guidelines currently recommend withholding GLP-1RAs prior to surgery, a measure deemed insufficient by some investigators[19].”
Adverse effects and other aspects of drugs with incretin effect
Ballesteros-Pomar, M. D., & Lesmes, I. B. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107041 · Cited by 4
Lithium toxicity with GLP-1RA co-prescription: clinical considerations and recommendations
Seth, S., & Ramanathan, S. (2025) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2025.100177 · Cited by 4
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Choudhuri, B. (2026) · Case Reports in Gastroenterology · doi:10.1159/000552414 · Cited by 2
“Tirzepatide also shows a similar delay in gastric emptying, with the strongest effects after initial doses [3, 4].”
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“GLP-1 RAs also delay gastric emptying, which contributes to satiety but may exacerbate symptoms in patients with pre-existing gastroparesis (He et al., 2022; Jalleh et al., 2024).”
Eldesouki, M. H., Alkasabrah, O., Kloub, M., Abosheaishaa, H. M., Elfert, K., Sharma, A., Andrawes, S., & Duong, N. K. (2026) · United European Gastroenterology Journal · doi:10.1002/ueg2.70238 · Cited by 3
Damhof, M., van Bruggen, F. V., & van Roon, E. V. (2026) · Diabetes, obesity and metabolism · doi:10.1111/dom.71075 · Cited by 2
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
“Because their efficacy and potential to chelate other medications depend on luminal contact with food and concomitant drugs, slowed gastric emptying may shift the timing of these interactions, so the dosing schedules of interacting oral agents may need to be adjusted accordingly [119].”
Kamoua, R., Paradine, K., & McCoy, L. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.09.007 · Cited by 2
Dumitru, C. N., Marcu, T., Dumitru, A. O., Tudor, S. S., Ferțu, I. D., Elisei, A.-M., & Goroftei, L. (2026) · Pharmaceuticals · doi:10.3390/ph19081313 · Cited by 2
“The second is pharmacokinetic: GLP-1 agonists slow gastric emptying and so alter the absorption rate of oral drugs [47,120], while berberine inhibits enzymes and transporters at the same intestinal interface, so the two perturb one process from different directions [46,47].”
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1
“This difference is believed to result from tachyphylaxis associated with prolonged GLP-1 RA use, leading to attenuation of the gastric emptying–delaying effect, which becomes more evident with long-acting formulations [32,33].”
Unmasking Gastroparesis in Diabetes During Ramadan: Challenges and Management Strategies
Abdulrasak, M., Shaat, N., Someili, A. M., & Mohrag, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061997 · Cited by 2
“…levels, patients undergoing the Ra-madan fast may experience more severe gastroparesis symptoms especially if large meals at Iftar are consumed [60–62]. patients undergoing the Ramadan fast may experience more severe gastroparesis symptoms especially if large meals at Iftar are consumed [60–62].”
Semaglutide‐Induced Silent Aspiration: An Unrecognised Cause of Organising Pneumonia
Essilfie‐Quaye, K., Maule, G., Hashim, H., Khraisat, M., Okonoboh, P., & Jantz, M. A. (2025) · Respirology Case Reports · doi:10.1002/rcr2.70249 · Cited by 2
Keng, C., Thor, S. M., Balasubramaniam, R., & Pretorius, F. (2025) · Cureus · doi:10.7759/cureus.99664 · Cited by 1
“Furthermore, GLP-1 and GLP-1RA are associated with the inhibition of migrating motor complex and increased small bowel transit time in patients with and without diabetes [12].”
Trykall, C. C., Hill, S. B., James, A. M., Bagnola, A. J., Wyne, K. L., Handley, D., & Brower, K. I. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.02.002 · Cited by 3
“16 Also, given the timeframe for inclusion criteria, only the post-recommendation group had patients taking tirzepatide, the GIP/GLP-1 RA, which has been considered clinically more effective for blood sugar control compared to GLP-1 RAs.”
Chang, S., Tang, Y., Wang, M., Zhu, S., Tan, X., Fan, X., Lu, L., Duan, B., & Shen, L. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062121 · Cited by 2
“GLP-1 RAs suppress the interdigestive migrating motor complex (MMC) [29], particularly the phase III activity responsible for clearing indigestible solids and fluids during fasting.”
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Self-citationMetabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
“By suppressing appetite and delaying gastric emptying, GLP-1RAs chronically reduce nutrient delivery from the diet [53].”
Biotransformation research advances—2025 year in review
Cheruzel, L., Argikar, U. A., Brunetti, P., Chatzopoulou, M., Chen, L., Cho, S., Dhaware, D., Heck, C. J. S., Honrao, C., Khojasteh, S. C., et al. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2666155 · Cited by 1
“Finally, as GLP-1 receptor agonists are known to delay gastric emptying (Jalleh et al. 2024), the pharmacokinetic profiles observed in these healthy participants may not fully translate to patients with altered gastric motility.”
Lista, S., Ballerio, M., López‐Ortiz, S., Khoramipour, K., Imbimbo, B. P., Santos‐Lozano, A., Minoretti, P., & Emanuele, E. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174217 · Cited by 1
Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics
Pitocco, D., Cortelletti, M., Petrucci, G., & Rocca, B. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.99 · Cited by 1
Салухов, В. В., Щеголев, А. В., Kryukov, E. V., Surzhikov, P. V., Apostolidi, E. V., & Prochik, Y. E. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-161 · Cited by 1
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
“As the small intestine is the primary site of drug absorption, this slower transit can affect the timing and, in some cases, the extent of absorption of orally administered medications [131].”
Li, Z., Yao, J., Wang, S., Xu, J., & Wu, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1799041 · Cited by 1
“For instance, leptin and insulin inhibit NPY/AgRP activity while upregulating POMC/CART neuronal excitability (65–68); similarly, GLP-1 receptor agonists enhance POMC/CART neuronal activity (69).”
Risiko durch GLP-1-Rezeptor-Agonisten vor Endoskopie und Narkoseeinleitung
Nauck, M. A., & Klein, H. H. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2607-5520 · Cited by 1
“wirksamen GLP-1-RA ist wohl ein vorübergehendes Phänomen und bei längerer Therapiedauer (etwa >20 Wochen) nur noch rudimentär oder gar nicht nachweisbar [2].”
Self-citationDajie, S., Yangzong, Z., & Yang, W. (2026) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000008151 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“Delayed gastric emptying, attributed to GLP-1R rather than GIPR, which is most pronounced after initial dosing and diminishes with continued therapy due to receptor adaptation [76, 77].”
Vasile, A., Anghel, A. C., Traşcă, T. I., & Orțan, A. (2026) · Nutrients · doi:10.3390/nu18142266 · Cited by 1
“Additionally, because it delays gastric emptying, it should be used with caution in people with severe gastrointestinal conditions such as gastroparesis [114,126].”
Valizada, H., & Zilbermint, M. F. (2026) · Cureus · doi:10.7759/cureus.113026 · Cited by 1
Controversies on the effects of GLP-1 receptor agonist treatment on gastric emptying
Rubio, M. Á., & Lesmes, I. B. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101538 · Cited by 2
Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70041 · Cited by 2
“…this to be related to delayed gastric emptying but noted, first, that longstanding type 2 diabetes accompanied by complications is strongly associated with delayed gastric emptying leading to retained gastric contents, and second, that this is infrequently associated with aspiration [11].”
Glucagon-like peptide-1 receptor agonists in orthopaedics
Mavrogenis, A. F., Altsitzioglou, P., Pililis, S., Anastasilakis, A. D., Tournis, S., Makras, P., Saranteas, T., & Lustıg, S. (2026) · SICOT-J · doi:10.1051/sicotj/2025067 · Cited by 2
Diabetic gastroparesis: pathophysiology and impact on insulin timing choices
Galeano, F., Tumminia, A., Oteri, V., Le Moli, R., Piticchio, T., Scilletta, S., Di Marco, M., Di Pino, A., & Frasca, F. (2026) · Endocrine · doi:10.1007/s12020-026-04693-6
Rubio, M. Á., & Lesmes, I. B. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.12.001 · Cited by 1
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Dobashi, H., Shioya, D., Kikkawa, K., Ohshima, K., Okada, J., & Okada, S. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf044
“The impact of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration has not been further investigated [3].”
Proteins and the crossroads of diet and type 2 diabetes
Anjom-Shoae, J., Wu, T., & Horowitz, M. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.08.004
Self-citationGLP-1 receptor agonist use for obesity in service personnel
Jecks, N., Hughes, C., Macleod, N., & Gifford, R. M. (2025) · BMJ Military Health · doi:10.1136/military-2025-003159
Scuderi, G. R., Ganz, M. P., & Mont, M. A. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.10.027
Wu, T., Rayner, C. K., Jones, K. L., & Horowitz, M. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00282-7
Self-citationThe Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP ‐1 Agonists
Wani, S., Findakly, S., Phan, T. D., Lukies, M. W., Goh, G. S., Venn, G., Joseph, T., Koukounaras, J., & Clements, W. (2025) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.70045
“Similarly, no heightened risk has been observed in postoperative or emergency surgery settings [49, 50].”
Case studies in disordered satiety and appetite
(2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29218-7.15002-3
Airway Management in the Age of GLP-1 Receptor Agonists
Valkeniers, K., Wallyn, A., de Putte, P. B. C. V., & Hogg, R. M. G. (2025) · Anesthesiology Clinics · doi:10.1016/j.anclin.2025.10.010
INTERNATIONAL GUIDELINES ON PERIOPERATIVE MANAGEMENT OF GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW
Grela, K., Grygorowicz, A., Baran, K., Ględa, M., Szyszka, M., Radecka, W., Kozak, W., Szreiber, A., Nowacka, K., Jabłoński, K., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4724
Shi, Y. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2025.07.032
Zhou, X., Liu, P., Zhao, G. T., Bai, D., Liu, W., Zeng, Y., Wan, R., Pan, H., & Mao, J. (2026) · Frontiers in Surgery · doi:10.3389/fsurg.2026.1733411
“However, because GLP-1 signaling is generally associated with delayed gastric emptying and reduced gastrointestinal transit, its role in accelerating early bowel function recovery is likely indirect and reflects broader postprandial coordination rather than a simple pro-motility mechanism (25).”
Mikaheal, Y., Hoang, J., Scott, A. M., Campbell, L., Du, Y., Ludington, J. E., Jones, K. L., & Greenfield, J. R. (2026) · Internal Medicine Journal · doi:10.1111/imj.70344
Self-citationLozada, G. A., Chen, R. B., Davoud, S. C., & Lee, G. S. (2026) · Anesthesiology Clinics · doi:10.1016/j.anclin.2026.02.002
Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03599-z · Cited by 1
“While pwCF are predisposed to such gastrointestinal adverse events, drugs such as semaglutide may increase this risk and thus particular caution is required [45, 46].”
Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions
Hajibandeh, S., Tao, Y.-A., Hsieh, M.-H., Liu, H.-H. “., Cheng, Y.-F., Lee, K.-H., Hsieh, S.-Y., & Lu, C. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103117
Oh, C.-S., Lee, S., & Hong, B. (2026) · Anesthesia and Pain Medicine · doi:10.17085/apm.26589
“Importantly, this gastroparetic effect does not reliably correlate with gastrointestinal symptoms, indicating that the absence of nausea, bloating, or vomiting cannot be used to infer gastric emptiness [12,16].”
Moyal, J., & Rehany, B. (2026) · University of Toronto Medical Journal · doi:10.33137/utmj.v103i2.46711
Yurukova, N., & Sultani, B. (2026) · Cureus · doi:10.7759/cureus.108793
“GLP1RAs delay gastric emptying in a dose-dependent manner, with the largest effect occurring after the first dose (a 70-90 min delay), followed by tachyphylaxis with subsequent doses [1,9,10].”
InfluentialInterpreting Glucagon-Like Peptide-1 Receptor Agonist–Associated Cough in Observational Data
Ragozzino, G., & Mattera, E. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2026.0938
Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use
Wang, A. L., Bach, L., & Leiman, D. A. (2026) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002395
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731
“While studies suggested that the delayed gastric emptying associated with GLP-1s may diminish over time due to tachyphylaxis [28-30] how this impacts the overall weight reduction effects of the drug over time is not yet known.”
Ballotin, V. R., Ferreira, P. L. C., de Almeida, V. T., Borges, C. D. S., de Almeida, H. T., da Silva, R. G. P., Volquind, D., & Selistre, L. D. S. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.121449
Voigt, J. H., Zubanovic, N. B., Møller, A. B., Suwal, S., Andersen, U., Andersen, H. H., Rittig, N. F., & Søndergaard, E. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101647
Soni, R., Goswami, D., Gani, A., Halami, P. M., & Chauhan, K. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00729-0
Beig, J., Ta, J., Jones, S., Scott, E., Sofi, K., Osler, F., Jansen, M., & Chhabra, P. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70059 · Cited by 1
“This observation has been reinforced in subsequent reviews [17, 25].”
Jacobsen, L., Viana, D. P. D. C., Folador, G. M., Schor, E., & Invitti, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135678
“%) of orally administered hormones [68].”
Metadata
- Authors
- Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A.
- Affiliations
- Royal Adelaide Hospital (AU)
- St. Josef-Hospital (DE)
- The University of Adelaide (AU)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Nauck, Michael A
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-17
- Volume
- 110
- Issue
- 1
- Pages
- 1-15
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC11651700
- OpenAlex
- W4403479516
- Cited by
- 157
- References
- 120
- Citations by year
- 2026: 110 · 2025: 45 · 2024: 2
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Funders
- Mary Overton postdoctoral fellowship
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- GLP-1 receptor agonists, tirzepatide, delayed gastric emptying, pulmonary aspiration, upper gastrointestinal endoscopy, periprocedural management, type 2 diabetes, obesity, tachyphylaxis, prokinetic agents, erythromycin, point-of-care ultrasound, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Emptying, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.